Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.

ABSTRACT:

Background

In recent years, there has been increasing evidence supporting the role of germline pharmacogenomic factors predicting toxicity for anticancer therapies. Although somatic genomic data are used frequently in oncology care planning, germline pharmacogenomic testing is not. This study hypothesizes that comprehensive germline pharmacogenomic profiling could have high relevance for cancer care.

Methods

Between January 2011 and August 2020, patients at the University of Chicago Medical Center were genotyped across custom germline pharmacogenomic panels for reasons unrelated to cancer care. Actionable anticancer pharmacogenomic gene/drug interactions identified by the FDA were defined including: CYP2C9 (erdafitinib), CYP2D6 (gefitinib), DPYD (5-fluorouracil and capecitab

SUBMITTER: Reizine NM 

PROVIDER: S-EPMC9153953 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature